A survivor of triple-negative breast cancer, Latasha Jordan, and an expert breast oncologist, Aditya Bardia, MD, MPH, provide key insights into the patient experience in triple-negative breast cancer and highlight the role of clinical trials in the current treatment landscape.
Direct-to-Bladder Immunotherapy Drug to Be Studied in Bladder Cancer
Chemo Combo Adds More to the Treatment Toolbox for Advanced Pancreatic NETs
Anniversary Time: A Look Back of What I’ve Learned 10 Years After Cancer
Taking 8-Plus Medications Before Cancer Treatment May Affect Effectiveness in Older Patients